Aiming at practical applications in which CDO1 methylation may serve as a biomarker, research on lung cancer [21], gastric cancer [22], colon cancer [23], HBV-related HCC [15], and cholangiocarcinoma [24] has been conducted. This evidence concerns the gene CDO1 and cholangiocarcinoma.